Kristen Klimbal, APRN
Psychiatric/Mental Health · Spartanburg, SCNPI 1083099857
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 314 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,146, 8.0 times the $270 reported in 2021. Among psychiatric/mental health clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$550
- Takeda Pharmaceuticals U.S.A., Inc.$518
- Otsuka America Pharmaceutical, Inc.$517
- Lundbeck LLC$445
- Neurocrine Biosciences, Inc.$396
- plus $2K from 18 others
What the payments were for
- Food & beverage$5,41997%
- Education$1513%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 97 | $1,011 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $550 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $518 |
| Otsuka America Pharmaceutical, Inc. | 23 | $517 |
| Lundbeck LLC | 23 | $445 |
| Neurocrine Biosciences, Inc. | 20 | $396 |
| Axsome Therapeutics, Inc. | 16 | $367 |
| Johnson & Johnson | 20 | $366 |
| Teva Pharmaceuticals USA, Inc. | 15 | $337 |
| E.r. Squibb & Sons, L.L.C. | 13 | $270 |
| Vanda Pharmaceuticals Inc. | 8 | $150 |
| Harmony Biosciences LLC | 3 | $115 |
| Corium, LLC | 6 | $112 |
| Acadia Pharmaceuticals Inc | 3 | $98 |
| Idorsia Pharmaceuticals US Inc | 5 | $82 |
| Alkermes, Inc. | 3 | $65 |
| Sunovion Pharmaceuticals Inc. | 2 | $34 |
| Eisai Inc. | 2 | $27 |
| Bristol Myers Squibb | 1 | $24 |
| Almatica Pharma LLC | 1 | $19 |
| Bioxcel Therapeutics, Inc. | 1 | $19 |
| Bausch Health US, LLC | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $18 |
| Lilly USA, LLC | 1 | $14 |
How this compares
$5,570 in reported general payments places this provider in the 90th percentile of 354 psychiatric/mental health providers in South Carolina.
See all psychiatric/mental health providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 143 | $220,927 |
| IngrezzaValbenazine Tosylate | 21 | $152,611 |
| Invega SustennaPaliperidone Palmitate | 56 | $125,150 |
| Austedo XrDeutetrabenazine | 18 | $119,491 |
| RexultiBrexpiprazole | 35 | $79,415 |
| TrintellixVortioxetine Hydrobromide | 46 | $55,403 |
| AuvelityDextromethorphan Hbr/Bupropion | 28 | $30,958 |
| Abilify MaintenaAripiprazole | 11 | $30,462 |
| Aripiprazole | 266 | $15,902 |
| Lurasidone Hcl | 35 | $10,143 |
| Paliperidone ErPaliperidone | 36 | $7,846 |
| Duloxetine Hcl | 234 | $7,484 |
| Quetiapine Fumarate | 378 | $7,259 |
| Trazodone Hcl | 451 | $6,597 |
| VyvanseLisdexamfetamine Dimesylate | 16 | $6,334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,011 | $220,927143 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $396 | $152,61121 claims |
| Johnson & JohnsonInvega Sustenna | $366 | $125,15056 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $337 | $119,49118 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $517 | $109,87746 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $518 | $61,73762 claims |
| Axsome Therapeutics, Inc.Auvelity | $367 | $30,95828 claims |
| Almatica Pharma LLCSertraline Hcl | $19 | $1,944279 claims |
| Lilly USA, LLCOlanzapine | $14 | $1,916112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 354 psychiatric/mental health providers in South Carolina.
Other psychiatric/mental health in Spartanburg
- Elizabeth CunninghamSpartanburg$4K
- Steven KrozerGreenville$139K
- Luron FlemingGreenville$61K
- Cerrissa HugieCharleston$54K
- Karen FulwoodMyrtle Beach$30K
- Taylor CrewsIsle Of Palms$28K
- Lauren DyerGreenville$16K
- Melissa BrownGreenville$16K
- Mary McManusNorth Myrtle Beach$15K
- Kelsie FowlerAnderson$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.